2. Search Result
Search Result
Results for "

DOTA-(t-butyl)3-PEG5-azide

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

8

Peptides

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10303
    Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)]

    Cyclo[RGDfK(azide)]

    		 Biochemical Assay Reagents Others
    Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is the derivative of Cyclo(-RGDfK) (HY-P0023). Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)] is a click chemistry reagent containing an azide group. Click chemistry has great potential for use in binding between nucleic acids, lipids, proteins, and other molecules, and has been used in many research fields because of its beneficial characteristics, including high yield, high specificity, and simplicity .
    Cyclo[Arg-Gly-Asp-D-Phe-Lys(Azide)]
  • HY-P10131
    3BP-3940

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    3BP-3940 is a highly potent and selective peptide inhibitor of FAP that targets cancer-associated fibroblasts (CAFs) in the tumor microenvironment. 3BP-3940 can be labeled with radionuclides (such as Ga-68) for precise tumor imaging or Lu-177 for the development of targeted anticancer technologies. 3BP-3940 accumulates in tumor lesions and can be used to diagnose and inhibit various solid cancers and CAFs-related diseases .
    3BP-3940
  • HY-P10273A
    DOTA-Octreotide TFA

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Cancer
    DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Octreotide TFA
  • HY-140753
    DOTA-(t-butyl)3-PEG5-azide

    		PROTAC Linkers Cancer
    DOTA-(t-butyl)3-PEG5-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . DOTA-(t-butyl)3-PEG5-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    DOTA-(t-butyl)3-PEG5-azide
  • HY-P10307
    DOTA-ubiquicidin (29–41)

    		Radionuclide-Drug Conjugates (RDCs) Bacterial Infection
    DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-ubiquicidin (29–41)
  • HY-P10444
    DOTA Conjugated JM#21 derivative 7

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA Conjugated JM#21 derivative 7
  • HY-P5297
    DOTA-CXCR4-L

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-CXCR4-L
  • HY-P10273
    DOTA-Octreotide

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Cancer
    DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Octreotide
  • HY-P2112
    DOTA-NOC

    DOTA-Nal3-octreotide

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Others
    DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-NOC

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: